Replies to post #119081 on Biotech Values

[mcbio]

I agree with jq1234 that Nexavar has been remarkably consistent across trials in PFS. In addition this trial is a homogeneous group of patients.

So I also take this as bullish for Aveo - I think this is a distinctly unappreciated stock as I believe it is going to be the drug of choice for VEGF combo therapy.

You and jq are two of the more knowledgeable posters on here and I imagine your instincts will probably be proven right. But, I just can't get past the whole Russian data deal again. ; )

What do you see as downside for AVEO if their drug manages to fail in Phase 3?